Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
December 21 2023 - 11:00AM
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage
immuno-oncology company focusing on developing next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications, announced today that the
Company’s management team will participate in Biotech Showcase and
present at the 19th Annual Non-Dilutive Funding Summit. Both events
will be held in-person and are scheduled alongside the J.P. Morgan
42nd Annual Healthcare Conference 2024.
Details of the events are as
follows:
Event: |
Biotech Showcase |
Date: |
January 8-10, 2024 |
Location: |
Hilton San Francisco Union Square |
Registration: |
https://informaconnect.com/biotech-showcase/registration-options/ |
Event: |
The 19thAnnual
Non-Dilutive Funding Summit |
Date: |
January 10, 2024 |
Location: |
Marines’ Memorial Club & Hotel, San Francisco |
Website: |
https://freemindgroup.com/19th-annual-non-dilutive-funding-summit/ |
Marker was awarded 2023 FreeMind Elite honoree,
a group of FreeMind Group clients that are selected annually and
honored for their achievements in pursuing non-dilutive funding. To
date, Marker has secured more than $17 million in non-dilutive
funding from various grant agencies, including FDA, NIH and Cancer
Prevention & Research Institute of Texas (CPRIT). As part of
the award announcement, Dr. Juan Vera, President and CEO of Marker
Therapeutics, will give a presentation at the 19th Annual
Non-Dilutive Funding Summit.
During J.P. Morgan week, members of the Marker
management team will conduct one-on-one meetings with registered
investors, showcasing the Company’s business and clinical
development, recent achievements, and anticipated
milestones.
About Marker Therapeutics,
Inc.Marker Therapeutics, Inc. is a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications. The T cell
therapy technology developed by Marker is based on the selective
expansion of non-engineered, tumor-specific T cells that recognize
tumor associated antigens (i.e., tumor targets) and kill tumor
cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient’s immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer the T cells, Marker believes that its product
candidates will be easier and less expensive to manufacture, with
reduced toxicities, compared to current engineered CAR-T and
TCR-based approaches, and may provide patients with meaningful
clinical benefit. As a result, Marker believes its portfolio of T
cell therapies has a compelling product profile, as compared to
current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email,
please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking StatementsThis
release contains forward-looking statements for purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Statements in this news release concerning Marker’s
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
“forward-looking statements.” Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research, development and regulatory activities and
expectations relating to our non-engineered multi-tumor antigen
specific T cell therapies; the effectiveness of these programs or
the possible range of application and potential curative effects
and safety in the treatment of diseases; and the timing, conduct
and success of our clinical trials of our product candidates.
Forward-looking statements are by their nature subject to risks,
uncertainties and other factors which could cause actual results to
differ materially from those stated in such statements. Such risks,
uncertainties and factors include, but are not limited to the risks
set forth in Marker’s most recent Form 10-K, 10-Q and
other SEC filings which are available through EDGAR
at WWW.SEC.GOV. Marker assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release
except as may be required by law.
ContactsTiberend Strategic
Advisors, Inc.
InvestorsDaniel
Kontoh-Boateng(862) 213-1398dboateng@tiberend.com
MediaCasey McDonald(646)
577-8520cmcdonald@tiberend.com
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024